CONTINUING RETROSPECTIVE AND PROSPECTIVE STUDIES BASED ON DETAILED CLINICAL

$1P01FY2009DKNIH

University Of Minnesota, Minneapolis MN

Investigators

Linked publications & trials

Paper 34089133 Paper 30102328 Paper 29677075 Paper 29498216 Paper 28980397 Paper 28681494 Paper 28557148 Paper 28376034 Paper 28371243 Paper 28342990 Paper 27712016 Paper 26888476 Paper 26479416 Paper 26327934 Paper 26095765 Paper 26021523 Paper 25847578 Paper 25183630 Paper 25148381 Paper 24831921 Paper 24696239 Paper 24632197 Paper 24547690 Paper 24528138 Paper 24414376 Paper 23935967 Paper 23813555 Paper 23712652 Paper 23711225 Paper 23687360 Paper 23647497 Paper 23539467 Paper 23432755 Paper 23290733 Paper 23157207 Paper 23094417 Paper 23062981 Paper 23023801 Paper 22917667 Paper 22574837 Paper 22385033 Paper 22343787 Paper 22282482 Paper 22241641 Paper 22017317 Paper 21812918 Paper 21772297 Paper 21659945 Paper 21659776 Paper 21508898 Paper 21446973 Paper 21233512 Paper 21219566 Paper 21158924 Paper 21150703 Paper 21051744 Paper 20118486 Paper 20105199 Paper 20041863 Paper 19958336 Paper 19623020 Paper 19543057 Paper 19496790 Paper 19459828 Paper 19459804 Paper 19395281 Paper 19394733 Paper 19358908 Paper 19353771 Paper 19295316 Paper 19179315 Paper 19136898 Paper 19133928 Paper 19100910 Paper 18925907 Paper 18782295 Paper 18662366 Paper 18528679 Paper 18375439 Paper 18003783 Paper 17998865 Paper 17697261 Paper 17617858 Paper 17536064 Paper 17467431 Paper 17418688 Paper 17414704 Paper 17302589 Paper 17294521 Paper 17100713 Paper 16877492 Paper 16824153 Paper 16771815 Paper 16731849 Paper 16686774 Paper 16565248 Paper 16518350 Paper 16436965 Paper 16394108 Paper 16162197

Abstract

Our preliminary data addressed some of our short-term end-points. We plan long-term follow-up to determine the impact of each of these immunosuppressive protocols on long-term kidney function. We will continue to do intention-to-treat analyses. However, we will also analyze subgroups that remain in their original randomized arm. One of the unexpected limitations of this study has been the high number of recipients that have not continued on one or both of the original study drugs. The multiple reasons for changes include inability to achieve study drug levels, AR, side effects, changes in local physician, and patient preference. Of note, national data show that a high percentage of transplant recipients have one of more of their immunosuppressive medications changed in the first 2 transplant years (32).

View original record on NIH RePORTER →